• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?

    2020-06-08 05:23:46IlariaLenciMartinaMilanaGiuseppeGrassiTommasoManziaCarloGaziaGiuseppeTisoneRobertaAngelicoLeonardoBaiocchi
    World Journal of Gastroenterology 2020年18期

    Ilaria Lenci, Martina Milana, Giuseppe Grassi, Tommaso M Manzia, Carlo Gazia, Giuseppe Tisone,Roberta Angelico, Leonardo Baiocchi

    Abstract Hepatitis B virus (HBV) recurrence after liver transplantation (LT) has been described more than 50 years ago. Similarly, to other clinical conditions, in which impairment of host immune defense favors viral replication, early reports described in details recurrence and reactivation of HBV in liver transplant recipients. The evidence of a possible, severe, clinical evolution of HBV reappearance in a significant percentage of these patients, allowed to consider,for some years, HBV positivity a contraindication for LT. Moving from the old to the new millennium this picture has changed dramatically. Several studies contributed to establish efficient prophylactic protocols for HBV recurrence and with the advent of more potent anti-viral drugs an increased control of infection was achieved in transplanted patients as well as in the general immunecompetent HBV population. Success obtained in the last decade led some authors to the conclusion that HBV is now to consider just as a “mere nuisance”.However, with regard to HBV and LT, outstanding issues are still on the table: (1)A standard HBV prophylaxis protocol after transplant has not yet been clearly defined; (2) The evidence of HBV resistant strains to the most potent antiviral agents is claiming for a new generation of drugs; and (3) The possibility of prophylaxis withdrawal in some patients has been demonstrated, but reliable methods for their selection are still lacking. The evolution of LT for HBV is examined in detail in this review together with the description of the strategies adopted to prevent HBV recurrence and their pros and cons.

    Key words: Liver transplant; Hepatitis B virus; Viral recurrence; Prophylaxis;Minimization; Antiviral drug

    INTRODUCTION

    The hepatitis B virus (HBV) is a small DNA virus belonging to theHepadnaviridaefamily[1]. Despite the adoption, in several countries, of an extended vaccination campaign starting in 1992, HBV infection still represents an important health problem with 350-400 million people infected in the world[2]. Without treatment, at least one third of patients are estimated to progress to significant liver disease, including endstage liver cirrhosis and tumors. In fact, the natural history of HBV liver disease includes a spectrum of clinical conditions ranging from a non-frequent fulminant hepatitis to HBV-related hepatocellular carcinoma and/or end-stage liver disease[3,4].While vaccination and the new antiviral drugs are effective, respectively, in avoiding HBV infection and preventing the most severe sequelae of HBV disease, liver transplantation (LT) remains the main therapeutic option in patients with more severe forms of HBV liver injury[5]. However, in the early 90's the possibility to offer LT to HBV candidates was an argument of debate. In fact, it was evident that HBV disease recurrence in the graft was severe in a significant proportion of patients[6]. Moreover,an aggressive clinical form of viral reactivation, named Fibrosing Cholestatic Hepatitis, was also described in nearly 25% of HBV transplanted patients, leading to a dramatic and rapidly progressive course[7]. Therapeutic advancement and prophylactic strategies against HBV radically changed this picture in the last three decades, allowing the consideration of HBV recurrence after LT to no longer be of concern. In this review we will describe HBV viral features, its natural history, and current outcome of HBV after LT.

    NATURAL HISTORY OF HBV

    HBV, a double stranded small DNA virus, replicating by reverse transcription, is able to convert its DNA in a covalently closed circular (ccc) form when reaching the hepatocyte's nucleus. cccDNA represents a mini-chromosome containing information for antigens (HBsAg, HBeAg, and HBcAg), X protein, and polymerase production[8].The infection route is mainly represented by vertical transmission in endemic areas.The estimated risk of acquiring the infection from an HBeAg+ mother is around 80%[9]. On the other hand, sexual or needle transmission are important paths in nonvaccinated adult patients of western countries[10]. Evolution of infection is dependent on the host, the viral genetics and virus/host interaction[3,11,12]. Vertical transmission at birth is associated (without peri-natal treatment) with a lifetime infection, usually with an immune-tolerant state[11]. This clinical situation is characterized by HBeAg positivity, high levels of HBV-DNA and normal liver function tests. Conversely, in adult normal subjects, immuno-tolerance usually lasts for 2-4 wk, the time span corresponding to the HBV incubation phase. Activation of the immune system against HBV determines: (1) Decreased HBV-DNA levels; (2) Increased liver inflammation;and (3) Elevation of serum levels of liver function tests. These features characterize the immune-active phase. This stage may evolve into: (1) Infection resolution with production of high titers of HBsAb (this target is reached by more than 90% of healthy adult individuals within 6 mo of initial HBV contact); (2) Fulminant hepatitis (rarely,≤ 0.5%); or (3) HBsAg persistence and evolution to chronic hepatitis[4]. During chronic hepatitis, the seroconversion to the HBeAg negative state (with development of HBeAb titer) represents an important achievement as it corresponds to decreased levels of HBV-DNA, liver inflammation and injury[13-15]. Moreover, HBeAg seroconversion with the consequent drop in HBV-DNA serum levels has been related to reduced fibrosis progression, histological staging, and onset of cirrhosis and hepatocellular carcinoma[16-18]. A subject with an acquired HBeAg negative state is usually defined as an inactive HBV carrier, referring to a remission state of the liver disease. Unfortunately, seroreversion to an HBeAg positive condition may occur over time (in approximately 20% of patients), also transiently, leading to a “de novo”immune-active inflammatory stage. Moreover, HBeAg loss (both spontaneous and drug induced) may determine selection in the host of pre-core mutants of HBV (not producing HBeAg). These strains are not affected, during their replicative phases, by anti-HBe antibodies, thus they determine progression of liver injury in approximately 10 to 30% of patients obtaining HBeAg loss[3,5,19]. The main clinical and virological features, in the different phases of HBV chronic infection, are reported in Table 1.From the above, it is evident that host-immune-system/virus interaction is a major determinant of the presence and severity of liver injury. This result is far more evident in subjects undergoing immune system changes related to biological or immunosuppressive therapies, including the majority of transplanted patients. In this setting severe reactivation of HBV is an element of concern[20].

    HBV DURING IMMUNE SYSTEM SUPPRESSION OR MODIFICATION (DRUG-INDUCED IMPAIRMENT OF THE IMMUNE SYSTEM AS A RISK FACTOR FOR HBV REACTIVATION)

    Reactivation of HBV is represented by sudden reappearance or increase of viral DNA in the serum of a patient with a resolved or clinically silent HBV infection[20]. This condition, which may also occur spontaneously, has been reported more frequently in patients undergoing immunosuppressive therapy for malignant or non-malignant disease[21]. In an early study in non-Hodgkin lymphoma patients under chemotherapy,HBV reactivation accounted for 72% of cases in HBsAg positive subjects[22]. More importantly, viral reappearance was also observed in HBsAb/HBcAb or only HBcAb positive subjects, thus suggesting the possibility of HBV reactivation also in conditions in which the infection was considered resolved in the past. Further studies also demonstrated HBV reappearance in non-neoplastic clinical settings such as Crohn's disease[23]or rheumatologic affections[24]. Treatment with biological agents,such as B-cell depleting (i.e., rituximab) or anti-tumor necrosis factor drugs(infliximab), carries a significant risk of HBV reactivation[25]. However, standard steroid treatment may also be responsible for HBV reappearance[26]. Evolution of viral reactivation is generally thought to occur in three separate phases[20,21]. At the beginning, a rise in HBV-DNA (at least ten-fold in comparison with baseline values) is observed during immunosuppressant treatment. In the second phase, when drugs are tapered or discontinued, the inflammatory damage begins, being triggered by the host immune defense that is also, in part, restored. In the last phase, the liver damage is repaired or may progress to end-stage liver failure. The evidence of a possible dramatic evolution of HBV reactivation in liver failure prompted the adoption of strategies to counteract this preventable occurrence. First of all, an adequate screening for HBV virus, including HBcAb, is proposed in individuals undergoing chronic therapy with immunologic modifiers. Secondly, antiviral agents able to prevent or cure this clinical condition are administered according to both viral and patient's features[27-29]. However, the clinical strategies commonly employed to prevent HBV reinfection are still lacking significant scientific evidence[27]. Therefore, the question of the best approach in different clinical scenarios remains open.

    Finally, the most important clinical setting in which HBV reappearance is a relevant issue is that of transplant. Transplanted patients usually require long-term high-dose immunosuppression to prevent rejection. In HBsAg positive patients undergoing bone marrow transplantation, HBV reactivation accounts for nearly the totality of cases[30]. Even in HBsAb/HBcAb+ subjects, reappearance of active HBV is not rare,accounting for nearly 20% of cases[31]. Starting from the early eighties, HBV reactivation was reported to be very frequent in the setting of kidney and heart transplantation, and it was characterized by the insurgence of HBV chronic hepatitis[20]. Indeed, HBV reactivation or recurrence also represents an important issue in liver transplanted patients. These subjects, in fact, share the same immunosuppressive need as other transplanted patients but, at the same time, are suffering the most important sequelae of HBV before surgery. This setting probably represents the most important clinical scenario in which dramatic HBV resurgence was observed

    Phase 1: lmmune tolerant Phase 2: lmmune active Phase 3: Asymptomatic carrier Phase 4: HBV reactivationand prophylactic measures were firstly pursued. At the same time, LT was the setting in which the risk of transplant with anti-core-HBV positive liver graft was identified.

    Table 1 Main virological and biochemical features in the different clinical phases of chronic hepatitis B in HBsAg+ patients

    HBV RECURRENCE IN THE EARLY TIMES OF LIVER TRANSPLANTATION (THE PURSUIT OF AN EFFECTIVE PROPHYLACTIC STRATEGY)

    HBV recurrence/reactivation after LT was already recognized almost 50 years ago[32].In the early 90's the feasibility of LT in HBV patients remained a crucial question since several reports observed viral recurrence in nearly all transplanted subjects, with an aggressive course in the larger part of them. While graft replacement was able to transiently reduce viral load, viral resurgence in the course of immunosuppression was related to significant liver damage and cirrhosis development[6,33]. So, at that time,LT in HBsAg positive patients was considered a high risk procedure for graft and patient loss, with an unacceptable hazard in particular in HBeAg+ subjects[34]. The disappointing results, and the need to pursue a solution for HBV patients with endstage liver disease, stimulated the research for a possible prophylactic therapy after LT. In a pioneering study conducted at Paul Brousse Hospital (Villejuif, France) in the eighties, an extended passive immune-prophylaxis was tested in HBsAg positive patients after LT[35]. Despite the monthly HBsAb immunoglobulin (HBIG)administration, 29% of patients experienced HBsAg and HBV-DNA reappearance in serum, however these data demonstrated the possibility to reduce HBV recurrence after LT. In a further European retrospective study on 372 HBV liver transplanted patients (between 1977 and 1990), a reduced rate of HBV reactivation was statistically associated with the absence of HBV-DNA before transplant and again to long-term passive immune prophylaxis with HBIG[36]. The exact mechanisms of the beneficial effects of immunoglobulin in this setting are not completely clear at present. Both reduced deletion of infected hepatocytes and prevention of viral aggression of liver cells have been suggested as possible effects[37]. Starting from the mid 90's, evidence was gathered on the role of lamivudine (Lam) treatment in repressing HBV replication[38,39]. Since, at that time, only HBIG-based prophylaxis was available after LT, and this therapy was a life-long, suboptimal, expensive treatment, the evaluation of the Lam effect in this clinical setting began. In an English study, 17 HBsAg positive patients were enrolled to receive Lam 4 wk before liver transplant and to continue 1 year thereafter[40]. Twelve out of seventeen patients were transplanted. In them, Lam induced a loss of HBsAg and undetectable HBV-DNA serum levels within 4 wk of treatment and after transplant. Moreover, liver histology did not show features suggesting HBV recurrence after LT, and these results were obtained without concomitant HBIG immune prophylaxis. Unfortunately, in the same study, selection of a resistant strain to Lam was observed in one patient after 20 wk of treatment. This occurrence was characterized by reactivation of HBV and evidence of chronic hepatitis on liver tissue after 1 year. Similar to that observed in HIV therapy[41], HBV strains not-responding to Lam were characterized by mutation of polymerase at the highly conserved YMDD motif[42-44]. With regard to liver transplanted HBV patients,extended follow up of Lam resistant patients was lately reported. Resistance to Lam began to occur, typically, six months after its introduction and was sometimes characterized by severe disease recurrence[45,46]. A combination of Lam therapy with HBIG was then attempted in order to further reduce HBV recurrence after LT. In a study, fourteen HBsAg positive LT patients were treated with Lam plus HBIG[47]. In a median follow-up of one year, all patients were HBV-DNA negative in serum, thus demonstrating the superiority of combination therapy in comparison with monotherapy with either Lam or HBIG. These data were also confirmed in a study with an extended (average 31 mo) follow-up[48]. Thus, the past millennium ended with the positive perspective that prevention of HBV recurrence/reactivation in HBsAg transplanted subjects was feasible. On the basis of these results, the possible exclusion of HBV subjects from transplant lists was largely reexamined.

    HBV RECURRENCE/REACTIVATION AFTER LIVER TRANSPLANTATION IN THE THIRD MILLENNIUM (TESTING NEW THERAPEUTIC APPROACHES AND DRUGS)

    The efficacy of passive immunization, in association with Lam, was again demonstrated in retrospective studies after the year 2000[49,50]. However, since this strategy was flawed by the relevant cost of HBIG and the need of life-long administration, the possibility to induce active immunization in HBV liver transplanted patients was examined.

    HBV vaccination

    In a study on 17 HBsAg+, HBeAg and HBV-DNA negative liver transplanted patients(after at least 18 mo of HBIG treatment), the double dose administration of HBV vaccine at baseline, 1 and 6 mo was tested[51]. After vaccination 84% of patients developed an HBsAb titer. During a further follow-up of 14 mo, HBsAg reappearance was not observed. These positive results were not replicated in a following study in which three reinforced and sequential cycles of HBV vaccination determined only a 17.6% HBsAb seroconversion in HBV transplanted patients[52]. In an editorial in the same journal, the limits of this strategy in transplanted patients were discussed,underscoring the scarce vaccine efficacy during immunosuppression and the long time needed to reconstitute the immune system after its depression[53]. In conclusion, it was confirmed that HBIG and antiviral therapy were regarded as the most appropriate measures against HBV recurrence after LT[54].

    Adefovir dipivoxil

    With regard to antiviral agents, in those years, a new drug implemented the armamentarium for the therapy of HBV. Adefovir dipivoxil (ADV), a nucleotide analog inhibiting viral reverse transcriptase that was abandoned for treatment of HIV because of kidney damage when used at high dose, was licensed for HBV treatment since it was active at lower, non-toxic levels for this virus (10 mg/d). ADV treatment in the majority of immune-competent HBsAg patients (both HBeAg positive or negative) determined a clear reduction of HBV-DNA, improvement of liver histology,and normalization of liver enzymes after a 48 wk course[55,56]. Moreover, emergence of ADV resistant mutants was not observed during these trials. Despite the fact that possible long-term viral resistance to ADV remained to be assessed, the efficacy of this new antiviral drug allowed hope for a new era in which HBV could be regarded as just a “mere nuisance”[57]. Soon, ADV was employed for the treatment of Lam resistant HBV after transplant[58]. Again, a significant improvement of liver function was recorded in nearly 90% of patients, and no resistant HBV strains were selected after 48 wk of therapy. However, ADV viral resistance was then observed with prolonged follow-up[59,60]. This was characterized by a novelN236Tmutation of HBV polymerase.In spite of this, the clinical evolution in patients was not worrisome since these ADV resistant strains were easily suppressed by Lam concomitant therapy. On the base of these findings, a possible Lam + ADV concomitant treatment for HBV was suggested[61]. Data from a systematic review including 2162 HBV LT patients[62]identified the following as possible risk factors for HBV recurrence: (1) Being HBVDNA positive at transplant (8.5%vs4%); (2) Administration of low dose HBIG in the first week after LT (6.1%vs3.5%); and (3) Combination therapy with HBIG + LamvsHBIG + ADV (6.1%vs2%). This picture was destined to undergo further changes with the advent of new nucleos(t)ide analogues with high genetic barriers.

    New high genetic barrier nucleos(t)ide analogues.

    Starting from 2012, entecavir (ETV) and tenofovir dipivoxyl (TDF) were proposed by several guidelines as a first line of treatment for chronic HBV hepatitis[5,63]. In fact, both drugs were demonstrated to be very effective in clinical studies, to have an excellent safety profile, and to be affected by a minimal or absent emergence of resistant HBV strains[64-68]. In a systematic review[69]on nucleos(t)ide analogues for HBV prophylaxis after LT, the comparison between Lam + HBIGvsthe association of ETV or TDF with HBIG demonstrated the superiority of the latter treatments (HBV recurrence rate 6.1%vs1%,P< 0.001). Moreover, in the same analysis, preliminary data evidenced slightly better results with either ETV or TDF monotherapy (after HBIG discontinuation) in comparison with the canonical Lam + HBIG prophylaxis (HBV recurrence rate 3.9%vs6.1%, difference not statistically significant). These findings introduced the concept of a possible minimization of HBV prophylaxis after LT, stimulating research with this target.

    TOWARD HBV PROPHYLAXIS MINIMIZATION AFTER LT

    Several strategies have been designed to minimize HBV prophylaxis after LT. The most relevant are described in the following subparagraphs with the corresponding results. Main studies on this issue are also summarized in Table 2.

    HBIG dose reduction

    Since long-term administration of HBIG was a critical point for its high cost, that would easily reach $100.000/pts/year[70], several attempts were carried out to reduce HBIG administration and acceptable results obtained. In a 2004 study conducted in our Unit (Liver Transplant Center, University of Rome Tor Vergata), we evaluated the possibility to prevent HBV recurrence after LT by administering HBIG on demand(when HBsAb serum levels were ≤ 70 IU/L) instead of the standard monthly administration[71]. Moreover, in the same study, two different HBIG doses (5000 IU or 2000 IU) were employed. In eleven HBV patients, at low risk for reactivation (HBsAg,HBV-DNA negative) and under concomitant Lam therapy, this strategy did not determine any HBV reactivation for 1 year follow up. On the other hand, the treatment based on administration of 2000 IU HBIG on demand reduced the cost of passive immune-prophylaxis by more than 50%. In 2007, the Australasian Liver Transplant Study Group assessed the association of very-low HBIG doses (400-800 IU)+ Lam on HBV recurrence after LT[72]. This strategy accounted for a modest HBV recurrence risk of 4% in 5 years, and the results were considered highly satisfactory since the majority of patients (85%) were HBV-DNA positive at transplant.

    High-genetic barrier nucleos(t)ide analogues monotherapy

    The advent of high-genetic barrier nucleos(t)ide analogues ETV and TDF, allowed speculation on a possible prophylaxis without HBIG. ETV monotherapy, tested on 80 patients undergoing LT for HBV, was able to suppress HBV-DNA (under the lower detection limit) in nearly 99% of cases after 24 mo[73]. Extended follow up of this study(8 years) demonstrated a 92% loss of HBsAg, while HBV-DNA was undetectable in all[74]. On the other hand, discontinuation of HBIG in transplanted patients treated with TDF + HBIG did not change any viral or patient profile in a 72 wk follow-up[75].Good results with either ETV and TDF were also replicated in other studies[76,77]. In a 5-year follow up in patients discontinuing HBIG and commencing either ETV or TDF after LT, HBsAg+ seroconversion occurred in 8% of cases, while HBV-DNA reappearance was not observed[78]. On the basis of these results, the most authoritative guidelines in the field now contemplate ETV or TDF monotherapy as an efficient prophylactic measure in subjects at low risk of HBV recurrence after LT[78,79].

    Complete withdrawal of HBV prophylaxis

    In the past years, our group examined a more radical approach to HBV prophylaxis minimization. This was characterized by the complete withdrawal of antiviral drugs in well selected HBV transplanted patients. We started with the assumption that reappearance of HBV after transplantation was dependent on the presence of cccDNA in the graft. Contrary to a North American study, (including several HBeAg/HBVDNA+ patients at LT) in which total HBV-DNA and cccDNA were detected in liver tissue in 83% and 18% of cases, respectively[80], in a preliminary evaluation of HBsAg patients transplanted in our center, only 1 out of 44 was found to be positive for cccDNA[81]. Among those that were negative for liver ccc-DNA, 30 were selected and underwent sequential withdrawal of HBIG and Lam. The majority of patients (83%,n= 25) did not experience any HBV recurrence in a median follow up longer than 2 years. Five patients came back to an HBsAg positive status. Prompt resumption of HBV prophylaxis allowed infection control, avoiding any significant clinical impairment[82]. From this study, we concluded that complete withdrawal of HBV prophylaxis after LT was feasible in patients with negative serum HBV-DNA and tissue cccDNA at transplant. An editorial, in the same journal, wisely observed that the time had come for an individualized prophylaxis in HBV transplanted patients[83].In fact, recurrence of HBV was mainly reported in patients who were HBV-DNA positive at transplant (> 100.000 copies/mL) and/or HBeAg+[36,72,84]. On the other hand, those not falling in the above category were considered at low risk for HBV recurrence. In this perspective, the target of HBV-DNA negativity was to be pursued before transplant in order to perhaps minimize prophylaxis after grafting. Conversely,for high-risk patients (HBeAg, HBV-DNA positive), more robust antiviral protocols were to be considered.

    Table 2 Main studies examining prophylaxis minimization in hepatitis B virus liver transplanted patients, employing different approaches

    More recently, data on longer (6-year) follow up of this original cohort were published by our group[85]. Only 3 patients needed prophylaxis resumption (10%). Of the whole cohort, 93% remained HBsAg negative and 100% had undetectable HBVDNA. More interestingly, 60% of patients spontaneously developed an HBsAb titer >10 IU/L. This was probably related to the minimization or withdrawal of antirejection therapy that is routinely pursued in our center in patients transplanted for several years. Comment on this study appeared in a new editorial[86]. While these data were encouraging, it underscored that limits remained in the identification of low risk patients. cccDNA techniques, in fact, needed to be standardized to be widely and consistently applicable in clinical settings, but on the other hand, extra-hepatic HBV reservoirs were still a possible issue of concern.

    CONCLUSION

    Several important achievements were obtained in the last fifty years with regard to HBV liver transplanted patients. The original exclusion of these subjects from LT waiting lists, due to poor outcome, was counteracted by the adoption of effective measures to prevent HBV recurrence. At present, high genetic barrier anti-viral drugs are giving an important contribution in transplanted patients, as well as in the HBV immune-competent population. Recently, tenofovir alafenamide, a TDF analog with improved renal safety and increased ability to reduce alanine aminotransferase, was employed in LT patients with good results[87]. However, of concern, HBV mutants with resistance to TDF (the drug with the highest genetic barrier) were recently identified, underscoring the need of a new generation of HBV agents to be employed,at least, as a rescue therapy[88]. The future of LT for HBV is not completely predictable at this stage. It will, however, depend on the global burden of HBV and the possible discovery of HBV eradicating drugs.

    久久99热这里只频精品6学生| 免费观看无遮挡的男女| 午夜精品在线福利| 尤物成人国产欧美一区二区三区| 国产欧美日韩精品一区二区| 精品一区二区三区人妻视频| 久久99热这里只有精品18| 精品久久久久久久久亚洲| 日本黄大片高清| 午夜日本视频在线| 国产成人精品婷婷| 丝袜美腿在线中文| 老司机影院成人| 国产一级毛片在线| 中文字幕av在线有码专区| 赤兔流量卡办理| 国产午夜精品论理片| 亚洲av成人精品一区久久| 国产精品女同一区二区软件| av一本久久久久| av一本久久久久| 国产综合精华液| 国产av国产精品国产| 亚洲精品影视一区二区三区av| 性色avwww在线观看| 99热6这里只有精品| 狠狠精品人妻久久久久久综合| 久久精品国产亚洲网站| 久久久久久伊人网av| 男女边摸边吃奶| 亚洲自拍偷在线| 只有这里有精品99| 欧美日韩在线观看h| av国产免费在线观看| 国产不卡一卡二| 欧美另类一区| 六月丁香七月| 人妻系列 视频| 免费观看精品视频网站| 久久久久久九九精品二区国产| 99久久中文字幕三级久久日本| 免费观看无遮挡的男女| 精品亚洲乱码少妇综合久久| 国产老妇女一区| 91av网一区二区| 噜噜噜噜噜久久久久久91| 久99久视频精品免费| 男女那种视频在线观看| 三级国产精品欧美在线观看| 亚洲av免费在线观看| 丰满少妇做爰视频| 观看免费一级毛片| 婷婷色av中文字幕| 亚洲丝袜综合中文字幕| 欧美精品一区二区大全| av一本久久久久| 一级黄片播放器| a级一级毛片免费在线观看| 我的老师免费观看完整版| 一级片'在线观看视频| 一本一本综合久久| 日韩电影二区| 2022亚洲国产成人精品| 天美传媒精品一区二区| 熟妇人妻不卡中文字幕| 日韩,欧美,国产一区二区三区| 国产av在哪里看| 少妇裸体淫交视频免费看高清| 久久精品国产亚洲网站| 日韩,欧美,国产一区二区三区| 黄片wwwwww| 国产高清有码在线观看视频| 亚洲人成网站在线播| 精品酒店卫生间| 3wmmmm亚洲av在线观看| 少妇猛男粗大的猛烈进出视频 | 久久久久精品性色| 午夜视频国产福利| 男的添女的下面高潮视频| 一边亲一边摸免费视频| 超碰97精品在线观看| 高清视频免费观看一区二区 | 欧美日韩亚洲高清精品| 免费看不卡的av| 亚洲av中文av极速乱| 狂野欧美激情性xxxx在线观看| 97精品久久久久久久久久精品| 午夜免费观看性视频| 22中文网久久字幕| 国产精品精品国产色婷婷| 亚洲人与动物交配视频| 国产探花极品一区二区| 欧美bdsm另类| 午夜精品在线福利| 色5月婷婷丁香| 欧美日韩在线观看h| 久久97久久精品| 晚上一个人看的免费电影| 久久精品国产亚洲av涩爱| 日本色播在线视频| 日韩欧美精品免费久久| 亚洲在线自拍视频| 亚洲精品乱码久久久久久按摩| 精品久久国产蜜桃| 国产单亲对白刺激| 国产午夜福利久久久久久| 午夜激情久久久久久久| 国产精品嫩草影院av在线观看| 中文字幕久久专区| 亚洲成人精品中文字幕电影| 国产精品久久视频播放| 尤物成人国产欧美一区二区三区| 天天躁夜夜躁狠狠久久av| 精品久久久久久久久av| 免费看日本二区| 夜夜爽夜夜爽视频| 国产黄片美女视频| 精品久久久久久久人妻蜜臀av| 午夜爱爱视频在线播放| 韩国av在线不卡| 晚上一个人看的免费电影| 啦啦啦韩国在线观看视频| 高清毛片免费看| 日韩欧美一区视频在线观看 | 国产一区有黄有色的免费视频 | 看十八女毛片水多多多| 天天躁夜夜躁狠狠久久av| 亚洲精品色激情综合| 亚洲最大成人av| 少妇猛男粗大的猛烈进出视频 | 国产久久久一区二区三区| 国产激情偷乱视频一区二区| 精品国产一区二区三区久久久樱花 | 亚洲欧美精品专区久久| 日产精品乱码卡一卡2卡三| 亚洲av中文av极速乱| 国产高清三级在线| 极品教师在线视频| 日日啪夜夜爽| 亚洲精品一区蜜桃| 久久久精品免费免费高清| 国产亚洲精品av在线| 十八禁网站网址无遮挡 | 亚洲精品aⅴ在线观看| 在线免费观看的www视频| 99久国产av精品国产电影| 国产日韩欧美在线精品| 国内精品美女久久久久久| 美女主播在线视频| 嫩草影院入口| 免费看av在线观看网站| av在线蜜桃| 欧美性猛交╳xxx乱大交人| 麻豆乱淫一区二区| 欧美+日韩+精品| 国产精品福利在线免费观看| 91精品伊人久久大香线蕉| 久久草成人影院| 久久亚洲国产成人精品v| 精华霜和精华液先用哪个| 国产免费视频播放在线视频 | av在线天堂中文字幕| 亚洲国产成人一精品久久久| 亚洲精品aⅴ在线观看| 日本免费a在线| 午夜精品国产一区二区电影 | 国产69精品久久久久777片| 亚洲av在线观看美女高潮| 国产毛片a区久久久久| av播播在线观看一区| 一级毛片电影观看| 男人和女人高潮做爰伦理| 中文字幕人妻熟人妻熟丝袜美| 久久久久久久久久成人| av天堂中文字幕网| 亚洲成人中文字幕在线播放| 久久久久九九精品影院| 尾随美女入室| 国产精品久久久久久精品电影| 日韩 亚洲 欧美在线| 人妻一区二区av| 免费看a级黄色片| 一级a做视频免费观看| 91av网一区二区| 中文资源天堂在线| 老女人水多毛片| 久久精品国产亚洲网站| 久久精品熟女亚洲av麻豆精品 | 免费看不卡的av| 天天躁夜夜躁狠狠久久av| 国产男人的电影天堂91| 少妇裸体淫交视频免费看高清| 人妻系列 视频| 大又大粗又爽又黄少妇毛片口| 成年女人看的毛片在线观看| 精品国产三级普通话版| 免费观看性生交大片5| 国产久久久一区二区三区| 午夜福利网站1000一区二区三区| 精品久久国产蜜桃| 国产在视频线在精品| 国产精品国产三级专区第一集| 啦啦啦中文免费视频观看日本| 国产高清三级在线| 国内揄拍国产精品人妻在线| 丰满少妇做爰视频| 国产探花在线观看一区二区| 久久这里只有精品中国| 国产单亲对白刺激| 国产午夜福利久久久久久| 搡老妇女老女人老熟妇| 国产亚洲av片在线观看秒播厂 | 国产精品熟女久久久久浪| 韩国高清视频一区二区三区| 国产av码专区亚洲av| 国产成人精品婷婷| 欧美高清性xxxxhd video| 成人毛片60女人毛片免费| 男女国产视频网站| 成人综合一区亚洲| 精品一区二区免费观看| 建设人人有责人人尽责人人享有的 | 一级a做视频免费观看| 国语对白做爰xxxⅹ性视频网站| 欧美3d第一页| 搡老乐熟女国产| av在线播放精品| 久久99热这里只频精品6学生| 精品久久久久久久久av| 亚洲国产精品成人综合色| 亚洲欧美中文字幕日韩二区| 中文资源天堂在线| 精品久久久久久久久亚洲| 免费观看性生交大片5| 色视频www国产| 美女被艹到高潮喷水动态| 人妻夜夜爽99麻豆av| 国国产精品蜜臀av免费| 一区二区三区乱码不卡18| 久久久久九九精品影院| 国语对白做爰xxxⅹ性视频网站| 国产 一区 欧美 日韩| 三级国产精品欧美在线观看| 床上黄色一级片| 国产69精品久久久久777片| 99re6热这里在线精品视频| 亚洲成人中文字幕在线播放| 麻豆国产97在线/欧美| 国语对白做爰xxxⅹ性视频网站| 亚洲图色成人| 亚洲成人av在线免费| 少妇丰满av| videossex国产| 亚洲av电影不卡..在线观看| 天天一区二区日本电影三级| eeuss影院久久| 精品久久久精品久久久| 高清在线视频一区二区三区| 三级经典国产精品| 少妇的逼好多水| 国产乱来视频区| 亚洲最大成人中文| 久久精品国产自在天天线| 欧美激情在线99| 成人二区视频| 天天一区二区日本电影三级| 少妇被粗大猛烈的视频| 女人十人毛片免费观看3o分钟| 成人性生交大片免费视频hd| 国产精品不卡视频一区二区| 人人妻人人澡欧美一区二区| 一夜夜www| 亚洲国产精品国产精品| 伦理电影大哥的女人| 成人国产麻豆网| 亚洲国产av新网站| 久久久精品94久久精品| 国产黄色视频一区二区在线观看| 免费黄色在线免费观看| 色5月婷婷丁香| 人人妻人人澡欧美一区二区| 淫秽高清视频在线观看| 国产v大片淫在线免费观看| 97超碰精品成人国产| 日韩av在线免费看完整版不卡| 日本爱情动作片www.在线观看| 亚洲精品中文字幕在线视频 | 美女内射精品一级片tv| 啦啦啦啦在线视频资源| 人妻制服诱惑在线中文字幕| 少妇人妻一区二区三区视频| 欧美zozozo另类| av在线老鸭窝| 欧美人与善性xxx| 美女国产视频在线观看| 午夜精品在线福利| kizo精华| 亚洲熟女精品中文字幕| 日本免费a在线| 麻豆av噜噜一区二区三区| 成人高潮视频无遮挡免费网站| 国产伦精品一区二区三区视频9| 精品久久久精品久久久| 黄色欧美视频在线观看| 22中文网久久字幕| 国产精品爽爽va在线观看网站| 免费av毛片视频| 最近视频中文字幕2019在线8| 亚洲成人久久爱视频| 日本一本二区三区精品| 欧美xxⅹ黑人| 久久精品久久久久久噜噜老黄| 亚洲内射少妇av| av女优亚洲男人天堂| 成人欧美大片| 免费观看在线日韩| 亚洲av中文av极速乱| 久久韩国三级中文字幕| 在线 av 中文字幕| 亚洲av一区综合| 直男gayav资源| 国产探花极品一区二区| 蜜臀久久99精品久久宅男| 免费大片18禁| 欧美xxxx性猛交bbbb| 亚洲无线观看免费| 成人国产麻豆网| 欧美性感艳星| 少妇熟女欧美另类| 国产精品.久久久| 亚洲精品乱久久久久久| 久久久国产一区二区| 久久99热这里只频精品6学生| 少妇人妻精品综合一区二区| kizo精华| 亚洲欧美精品专区久久| 免费不卡的大黄色大毛片视频在线观看 | 国产精品一区二区三区四区久久| 亚洲婷婷狠狠爱综合网| 国产乱人偷精品视频| 久久鲁丝午夜福利片| 亚洲国产精品sss在线观看| 亚洲欧美清纯卡通| 国产 一区 欧美 日韩| 天堂中文最新版在线下载 | 一区二区三区高清视频在线| 国产精品精品国产色婷婷| 亚洲精品中文字幕在线视频 | 成年女人看的毛片在线观看| 国产精品日韩av在线免费观看| 丝瓜视频免费看黄片| 久久久a久久爽久久v久久| 国产一区二区三区av在线| 人妻系列 视频| 日日啪夜夜撸| 青春草国产在线视频| 男人舔奶头视频| 免费黄色在线免费观看| 日日啪夜夜撸| 一级av片app| 91久久精品电影网| 亚洲人与动物交配视频| 免费高清在线观看视频在线观看| 69人妻影院| 国产精品人妻久久久久久| 日韩不卡一区二区三区视频在线| 久久国内精品自在自线图片| 少妇高潮的动态图| 久久韩国三级中文字幕| 亚洲色图av天堂| 91在线精品国自产拍蜜月| 在线播放无遮挡| 夫妻午夜视频| 亚洲欧美成人精品一区二区| 麻豆国产97在线/欧美| 黄色欧美视频在线观看| 有码 亚洲区| 国产黄色视频一区二区在线观看| 久久精品熟女亚洲av麻豆精品 | 91午夜精品亚洲一区二区三区| 亚洲欧美日韩无卡精品| 69人妻影院| 美女被艹到高潮喷水动态| 亚洲精品成人久久久久久| 欧美xxxx黑人xx丫x性爽| 国产精品麻豆人妻色哟哟久久 | 婷婷色av中文字幕| 男女边摸边吃奶| 一本一本综合久久| 日本免费在线观看一区| 有码 亚洲区| 日日啪夜夜爽| 国产精品福利在线免费观看| 婷婷色综合www| 黄色配什么色好看| 精品久久久久久久久av| 狠狠精品人妻久久久久久综合| 永久免费av网站大全| 国产成年人精品一区二区| 成人鲁丝片一二三区免费| 日本-黄色视频高清免费观看| 嫩草影院精品99| 午夜福利成人在线免费观看| 日韩欧美 国产精品| 一级毛片电影观看| 天堂√8在线中文| 又爽又黄无遮挡网站| 最近中文字幕2019免费版| 99热网站在线观看| 亚洲国产成人一精品久久久| 日韩av不卡免费在线播放| 午夜免费激情av| 亚洲无线观看免费| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 欧美三级亚洲精品| 久久精品综合一区二区三区| 日本黄色片子视频| 夫妻性生交免费视频一级片| 日本色播在线视频| 男女视频在线观看网站免费| 赤兔流量卡办理| 97超视频在线观看视频| 日本免费在线观看一区| 日日干狠狠操夜夜爽| 国产激情偷乱视频一区二区| 久久99热这里只有精品18| 国产黄色视频一区二区在线观看| 久久鲁丝午夜福利片| 亚洲av福利一区| 成人亚洲精品av一区二区| 久久久成人免费电影| 伊人久久国产一区二区| 亚洲国产欧美在线一区| 亚洲精品乱码久久久v下载方式| 精品一区二区免费观看| 观看免费一级毛片| 国产亚洲91精品色在线| 久久久久免费精品人妻一区二区| 嫩草影院新地址| 色5月婷婷丁香| 最近中文字幕高清免费大全6| 一个人看的www免费观看视频| 六月丁香七月| 久久久久久久久久久丰满| 七月丁香在线播放| 亚洲丝袜综合中文字幕| 97在线视频观看| 成人综合一区亚洲| 一级a做视频免费观看| 成年女人在线观看亚洲视频 | 亚洲欧洲国产日韩| 男人爽女人下面视频在线观看| 久久久久久久久久人人人人人人| 最近视频中文字幕2019在线8| videos熟女内射| 日产精品乱码卡一卡2卡三| 亚洲高清免费不卡视频| 亚洲精华国产精华液的使用体验| 最近最新中文字幕免费大全7| 极品教师在线视频| 日韩精品有码人妻一区| 又黄又爽又刺激的免费视频.| 日韩欧美 国产精品| 99久久精品国产国产毛片| 久久久久久九九精品二区国产| 美女高潮的动态| 欧美日韩精品成人综合77777| 如何舔出高潮| 日韩大片免费观看网站| 免费人成在线观看视频色| 狂野欧美激情性xxxx在线观看| ponron亚洲| 国产黄色视频一区二区在线观看| 深夜a级毛片| 亚洲av在线观看美女高潮| 国产精品一及| 夜夜爽夜夜爽视频| 一级二级三级毛片免费看| 国产亚洲精品av在线| 嫩草影院新地址| 亚洲成色77777| 丝袜美腿在线中文| 成人毛片60女人毛片免费| 麻豆乱淫一区二区| 少妇丰满av| 欧美一级a爱片免费观看看| 男女国产视频网站| 国产成人精品福利久久| 久久久久网色| 91午夜精品亚洲一区二区三区| 久久久久性生活片| 热99在线观看视频| 乱码一卡2卡4卡精品| 亚洲欧洲日产国产| 国产午夜精品一二区理论片| 国产黄色小视频在线观看| 国产熟女欧美一区二区| 日韩 亚洲 欧美在线| 免费观看a级毛片全部| 午夜福利成人在线免费观看| 亚洲18禁久久av| 小蜜桃在线观看免费完整版高清| 一区二区三区四区激情视频| 人妻夜夜爽99麻豆av| 一级毛片我不卡| 亚洲经典国产精华液单| 一级二级三级毛片免费看| 欧美高清成人免费视频www| 亚洲内射少妇av| 国产 一区 欧美 日韩| 国产免费一级a男人的天堂| 久久精品夜夜夜夜夜久久蜜豆| 国模一区二区三区四区视频| 国产亚洲精品av在线| 国产精品av视频在线免费观看| 国产精品久久久久久精品电影小说 | 日本午夜av视频| 国产视频内射| 精品熟女少妇av免费看| 亚洲高清免费不卡视频| 成人高潮视频无遮挡免费网站| 中国国产av一级| 午夜免费观看性视频| 身体一侧抽搐| 久久久久精品性色| 在线观看av片永久免费下载| 欧美日韩国产mv在线观看视频 | 午夜免费激情av| 成人亚洲欧美一区二区av| 大香蕉97超碰在线| 在线天堂最新版资源| 嫩草影院入口| 久久久久国产网址| 一区二区三区免费毛片| 亚洲成人av在线免费| 午夜免费激情av| 欧美精品一区二区大全| 非洲黑人性xxxx精品又粗又长| 国产亚洲5aaaaa淫片| 亚洲成人久久爱视频| 亚洲精品久久久久久婷婷小说| 亚洲人与动物交配视频| 男女啪啪激烈高潮av片| 18禁裸乳无遮挡免费网站照片| 亚洲欧美一区二区三区黑人 | 天美传媒精品一区二区| 精品久久久久久久人妻蜜臀av| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 日韩亚洲欧美综合| 欧美不卡视频在线免费观看| 色播亚洲综合网| 久久久久久久久久久免费av| 日本爱情动作片www.在线观看| 91狼人影院| 少妇裸体淫交视频免费看高清| 久久亚洲国产成人精品v| 我要看日韩黄色一级片| 80岁老熟妇乱子伦牲交| 精品久久国产蜜桃| 99久久精品一区二区三区| 亚洲18禁久久av| 波多野结衣巨乳人妻| 国产精品爽爽va在线观看网站| 国产精品人妻久久久久久| 偷拍熟女少妇极品色| 国产毛片a区久久久久| 色播亚洲综合网| 伦理电影大哥的女人| 美女内射精品一级片tv| 三级男女做爰猛烈吃奶摸视频| 日韩欧美精品免费久久| 你懂的网址亚洲精品在线观看| 国产成人a∨麻豆精品| 国产精品一区二区三区四区免费观看| 啦啦啦中文免费视频观看日本| 99久久九九国产精品国产免费| 少妇猛男粗大的猛烈进出视频 | 免费大片黄手机在线观看| 国产免费视频播放在线视频 | 卡戴珊不雅视频在线播放| 国产精品99久久久久久久久| 天美传媒精品一区二区| 天天一区二区日本电影三级| 亚洲欧美日韩卡通动漫| 黄色日韩在线| 日本av手机在线免费观看| 97精品久久久久久久久久精品| 亚洲av国产av综合av卡| 麻豆精品久久久久久蜜桃| 亚洲精品aⅴ在线观看| 非洲黑人性xxxx精品又粗又长| av免费观看日本| 熟妇人妻不卡中文字幕| 少妇被粗大猛烈的视频| 国产精品久久久久久久久免| 亚洲欧洲国产日韩| 老女人水多毛片| 国产精品一区二区三区四区久久| 中文字幕久久专区| 激情五月婷婷亚洲| 日韩欧美一区视频在线观看 | 一本一本综合久久| 男女啪啪激烈高潮av片| 久久99热6这里只有精品| 日韩制服骚丝袜av| 99久久人妻综合| 亚洲av免费在线观看| 99热这里只有是精品50| 精品久久久久久久久av| 91精品一卡2卡3卡4卡| 国产黄片视频在线免费观看| 国内精品一区二区在线观看| 一级二级三级毛片免费看| 看十八女毛片水多多多| 一区二区三区免费毛片|